Article
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
2020-08-07
Abstract excerpt
<h4>Summary</h4> Despite the genetic inactivation of SMARCA4 , a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. Thi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d838c376-33a0-5909-beb5-3b28209c425b
- DOI
- 10.1101/2020.08.07.241232
